Stimulation of neoangiogenesis in patients with chronic ischemic lower extremities by autological progenitor bone morrow cells


The results of neoangiogenesis has been studied for the treatment of 42 patients with arterial atherosclerosis occlusive disease of lower extremities who are not candidates for treatment surgical. We studied the results in the 3 groupies including 14 patients in the each. Autological progenitor cells (CD 133+) were transplanted in I-st group. Leucocytes bone morrow cells (CD 34+) were transplanted in II group. The patients of III group was injected isotonic solution as a placebo. All of solutions were injected in internal and external muscles of shin. We appreciated our clinical results in Rutherford's scale. In conclusion, we observed what the improvement of clinical condition in patients (with a transplantation of CD 133+ and CD 34+ of I and II groups) was trustworthy by Mann-Whitney's criterion.

About the authors

A V Kazantsev

Email: dockazantsev@


  1. Савельев В. С., Кошкин В. М. Критическая ишемия нижних конечностей. М.- Медицина. - 1997. - 160 с.
  2. Покровский А. В. Клиническая ангиология: Руководство для врачей.- М.: Медицина,- 2004. - Том 2. - 888 с.
  3. Гавриленко А. В., Воронов Д. А., Фомичева И. И. Генно-инженерные технологии стимуляции ангиогенеза в лечении хронической ишемии нижних конечностей // Анналы хирургии. - 2005. - № 4. - С. 5-8.
  4. Canizo M. C., Lozano F., Gonzalez-Porras J. R. et al. Peripheral endothelial progenitor cells (CD133+) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up // Cytotherapy. - 2007. - Vol. 9, № 1. - P. 99-102.
  5. Dong-Ik Kim, Mi-Jung Kim, Jin-Hyun Joh. et al. Angiogenesis facili-tated by autologous whole bone marrow stem cell transplantation for Buerger's disease // Stem Cells. - 2006. - № 24. - P. 1194-1200.



Abstract - 24


Article Metrics

Metrics Loading ...




  • There are currently no refbacks.

Copyright (c) 1970 Kazantsev A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies